TScan Therapeutics (TCRX) Stock: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$0.22
-0.01 (-3.48%)
▼
5d:
-9.65%
30d:
-40.6%
90d:
-72.77%
HOLD
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $0.22, which is considered oversold relative to its 30-day fair value range of $0.25 to $0.34.
Technical Outlook: Technically, TCRX is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.25. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: TCRX scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.00 (+362.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TCRX is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.25. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: TCRX scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.00 (+362.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.25 -
$0.34
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 362.5% below Wall St target ($1.00)
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.25 -
$0.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.20
Resistance Level
$0.25
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.38
Wall Street Target
$1.00
(+362.5%)
Revenue Growth (YoY)
-65.8%
Share & Embed Analysis
Last updated: October 23, 2026 9:11 AM ET
Data refreshes hourly during market hours. Next update: 10:11 AM
Data refreshes hourly during market hours. Next update: 10:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |
